Clinical Trial Update: Use of Activated Recombinant Human Factor VII in Cardiac Surgery [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating activated recombinant human factor VII for bleeding control in cardiac surgery requiring cardiopulmonary bypass was terminated. No resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acquired Bleeding Disorder

Drugs mentioned

• Activated Recombinant Human Factor VII (Factor VIIa)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Acquired Bleeding Disorder, Cardiac Surgery Requiring Cardiopulmonary Bypass | Phase 2 | Status: TERMINATED